Medical Writing Observational Studies EMA releases the revised Good Pharmacovigilance Practices Module V – updated guidance on risk management plans
emwa-autumn-2017-cover-image

Volume 26, Issue 3 - Observational Studies

EMA releases the revised Good Pharmacovigilance Practices Module V – updated guidance on risk management plans

Abstract

Recently, the EMA released the revised Module V – Risk Management Systems (Rev 2) of Good Pharmacovigilance Practices (GVP) accompanied by a revised version of the guidance on the format of the risk management plan (RMP) in the EU – in integrated format. The revision will result in concise, scientifically focussed and riskproportionate documents and is applicable to all sections of the RMP, especially sections that have become overly lengthy over time and often duplicate information presented elsewhere in the dossier or in other documents, such as the periodic safety update report.
Download the full article

References

  1. Good pharmacovigilance practices. European Medicines Agency. [cited 2017 Jun 12]. Available from: Available from: http://www.ema.europa.eu/ema/index.jsp? curl=pages/regulation/document_listing/document_listing_000345.jsp
  2. Guidelines on good pharmacovigilance practices (GVP). Introductory cover note, last updated with draft revision 2 of module V on risk management system for public consultation. EMA/136477/2016. 2016 Feb 29 [cited 2017 Jun 12]. Available from: Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_ procedural_guideline/2017/03/WC500224566.pdf
  3. European Medicines Agency’s interaction with industry stakeholders. Annual Report 2015. EMA/774549/2015. 2016 Jun 16 [cited 2017 Jun 12]. Available from: Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2016/06/WC500208988.pdf
  4. Guideline on good pharmacovigilance practices (GVP). Module V – Risk management systems (Rev 2) – draft for public consultation. European Medicines Agency and Heads of Medicines Agencies. 2016 Feb 24 [cited 2017 Jun 12]. Available from: Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2016/02/WC500202424.pdf
  5. Draft guidance on format of the risk management plan (RMP) in the EU – in integrated format. EMA/PRAC/613102/ 2015 Rev.2 accompanying GVP Module V Rev.2. European Medicines Agency. 2016 Feb 29 [cited 2017 Jun 12]. Available from: Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/document_detail.jsp?webContentId=WC500202373&mid=WC0b01ac058009a3dc
  6. GVP Module V–Risk management systems, EMA/838713/2011 Rev 2. European Medicines Agency and Heads of Medicines Agencies. 2017 Mar 28 [cited 2017 Jun 12]. Available from: Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129134.pdf
  7. Guidance on format of the risk management plan (RMP) in the EU – in integrated format. European Medicines Agency and Heads of Medicines Agencies. 2017 Mar 30 [cited 2017 Aug 18]. Available from: Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2017/03/WC500224770.docx
  8. Guideline on good pharmacovigilance practices (GVP). Module V – Risk management systems (Rev 1). European Medicines Agency and Heads of Medicines Agencies. 2014 Apr 15 [cited 2017 June 12]. Available from: Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific _guideline/2012/06/WC500129134.pdf

Search

Articles

Observations and Observational Studies
President's Message
EMWA News
RCTs: Can the treatment work? Patient registries: Does the treatment work?
Odd cases and risky cohorts: Measures of risk and association in observational studies
Guidance for the design and analysis of observational studies: The STRengthening Analytical Thinking for Observational Studies (STRATOS) initiative
Guidelines for disclosing the results from observational trials
Registration and ethics committee approval for observational studies: Current status and way forward
Regulatory submissions of non-interventional post-authorisation safety studies
Reporting non-interventional post-authorisation safety studies (NI-PASS)
Patient-reported outcomes: How useful are they?
EMA releases the revised Good Pharmacovigilance Practices Module V – updated guidance on risk management plans
Mentoring tomorrow’s medical writers
ICMJE to mandate data sharing statements
News from the EMA
Journal Watch
Getting Your Foot in the Door
In the Bookstores
Regulatory Matters
Medical Communications
The Webscout
Teaching Medical Writing
Good Writing Practice
Out on Our Own

Member Login

Links

The Write Stuff Archive Contact Instructions for Authors Feature Article Template (Word) Journal Policies

Editoral Board

Editor-in-Chief:

Co-Editor:

Managing Editor

  • Victoria White (Tampa, Florida, USA) Email: MEW@emwa.org
show all +

Associate Editors:

Section Editors:

Ad-hoc Editors:

  • Amy Whereat (SpeaktheSpeech Consulting, Asnieres sur Seine, France)

Editor Emeritus: